IQVIA Holdings Inc. (NYSE:IQV) Holdings Raised by Summit Trail Advisors LLC

Summit Trail Advisors LLC boosted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 46.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,855 shares of the medical research company’s stock after buying an additional 587 shares during the period. Summit Trail Advisors LLC’s holdings in IQVIA were worth $365,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of IQV. Capital Performance Advisors LLP bought a new stake in shares of IQVIA in the 3rd quarter worth $27,000. Synergy Asset Management LLC acquired a new position in IQVIA during the fourth quarter worth about $33,000. Avior Wealth Management LLC raised its position in IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after acquiring an additional 87 shares in the last quarter. Assetmark Inc. lifted its holdings in IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 196 shares during the last quarter. Finally, Concord Wealth Partners acquired a new position in shares of IQVIA in the 3rd quarter worth approximately $57,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insiders Place Their Bets

In other IQVIA news, Director John G. Danhakl acquired 1,275 shares of IQVIA stock in a transaction that occurred on Tuesday, December 3rd. The stock was acquired at an average price of $200.58 per share, with a total value of $255,739.50. Following the purchase, the director now owns 1,275 shares in the company, valued at approximately $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.60% of the company’s stock.

IQVIA Price Performance

Shares of NYSE:IQV opened at $197.64 on Thursday. The business has a fifty day simple moving average of $200.77 and a 200 day simple moving average of $218.81. The company has a current ratio of 0.84, a quick ratio of 0.81 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The firm has a market cap of $35.87 billion, a price-to-earnings ratio of 26.35, a P/E/G ratio of 2.25 and a beta of 1.48.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.81 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently commented on IQV shares. UBS Group cut their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Morgan Stanley increased their price objective on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday. JPMorgan Chase & Co. decreased their target price on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Finally, Bank of America dropped their price target on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Five analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $251.67.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.